Michael Boeckh, MD, PhD (Chair)
Member, Vaccine and Infectious Disease & Clinical Research Divisions
Head, Infectious Disease Sciences Program
Fred Hutchinson Cancer Research Center
Professor of Medicine, University of Washington
Seattle, WA

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Infection Control Section
Director of Clinical Virology
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, TX

Genovefa Papanicolaou, MD
Associate Member
Memorial Sloan-Kettering Cancer Center
New York, NY

Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath
Professor of Transplant Science and Cancer Immunotherapy
UCL Cancer Institute
University College London Hospitals
London, England

Jointly Provided By

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 1.25 AMA PRA Category 1 Credit
Release Date: March 15, 2017
Expiration Date: March 14, 2018
Estimated Time to Complete Activity: 1.25 hours
Registration Required: No
Fee for Activity: There is no fee for this educational activity.

Activity Description

This activity is based on the proceedings from the live symposium and focuses on the treatment and management of cytomegalovirus (CMV) in stem cell transplant. This activity includes audio recording from the live meeting and interactive polling questions.

Learning Objectives

After completing this activity, participants should be better able to:

  • Discuss the application of CMV viral load kinetics to clinical practice and in the development of emerging therapeutics
  • Summarize CMV treatment drugs in late clinical development including potential toxicities and advantages over existing therapies
  • Explain the mechanisms and logistics of CMV cellular immunotherapy and vaccines in immunocompromised stem cell transplant patients
  • Apply existing and emerging management strategies to improve patient health outcomes in refractory and resistant CMV disease

Target Audience

This activity has been designed to meet the educational needs of hematology physicians, oncology physicians, scientists, and hematology trainees who manage CMV infection in patients that undergo hematopoietic stem cell transplant (HSCT).

Requirements for Successful Completion




Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Michael Boeckh, MD, PhD, has affiliations with Chimerix, Inc., Merck, Microbiotix, Astellas, Shire, Helocyte, Inc., Oxford Immunotec (Consulting Fees); Astellas, Chimerix, and Merck (Research).

Roy F. Chemaly, MD, MPH, FIDSA, FACP, has affiliations with Oxford Immunotec, Merck, Astellas, Chimerix (Advisory Boards); Oxford Immunotec (Speakers’ Bureau); Merck, Chimerix (Research).

Genovefa Papanicolaou, MD, has affiliations with Shire, Chimerix, Astellas, Genentech, Merck (Consulting Fees); Merck, Astellas (Research).

Karl S. Peggs, MB, BCh, MA, MRCP, FRCPath, has no affiliations with commercial interests to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI Medical Education, LLC
• Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
• Faith Reidenbach, CMPP, CHCP, has no affiliations with commercial interests to disclose.
• Nora Hartley has no affiliations with commercial interests to disclose.

Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.25 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Credit Available
Physicians – maximum of 1.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation

Statement of Commercial Support

Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by an independent medical educational grant from Shire.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware / Software Requirements

OpenCME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.